Skip to content

International Lung Screen Trial (ILST)

International Lung Screen Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02871856
Acronym
ILST
Enrollment
2000
Registered
2016-08-18
Start date
2017-04-05
Completion date
2025-12-31
Last updated
2023-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Non-small Cell Lung Cancer, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Smokers at Risk of Lung Cancer, Thoracic Neoplasms

Keywords

Screening, Computed tomography, Lung cancer

Brief summary

People who may be at increased risk of lung cancer due to age and smoking history will be invited to participate in this international study to determine the best way of using computed tomography (CT) of the chest to screen for early lung cancer. Overseas data show that CT screening (screening tests can find diseases early, when they're easier to treat) can reduce deaths from lung cancer and this study will help determine who is most likely benefit from screening.

Detailed description

\[insert site name\]

Interventions

DIAGNOSTIC_TESTLow dose CT

low-dose screening CT of chest for lung cancer detection

Sponsors

The University of Queensland
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
55 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Inclusion Criteria: * Women or men age from 55 to 80. * Current or former smokers. A former smoker is defined as one who has stopped smoking for one or more years. * An estimated 6-year lung cancer risk of ≥1.51% based on the PLCOm2012 risk prediction model or ≥ 30 pack-years smoking history (pack-year is defined as number of pack of cigarettes smoked per day multiply by the number of years smoked. If a participant stopped smoking for 6 months or more and then restarted smoking again, the time will be subtracted from the total duration of smoking in 0.5 year increments) * ECOG performance status 0 or 1. * Capable of providing, informed consent for screening procedures (low dose spiral CT) *

Exclusion criteria

* Clinical symptoms suspicious for lung cancer e.g. hemoptysis, chest pain, weight loss * Any medical condition, such as severe heart disease (e.g. unstable angina, chronic congestive heart failure), acute or chronic respiratory failure, home oxygen therapy, bleeding disorder, that in the opinion of the investigator could jeopardize the subject's safety during participation in the study or unlikely to benefit from screening due to shortened life-expectancy from the co-morbidities * Have been previously diagnosed with lung cancer * Have had other non-curatively treated cancer outside the lung. * Pregnancy * Pneumonia or bronchitis requiring antibiotic treatment within the last 12 weeks * Unwilling to have a spiral chest CT * Chest CT within 2 years * Does not fit into CT scanner table due to gross obesity * Cannot lie on CT scanning table on the back with arms over the head * Received chemotherapy or cytotoxic drugs within the last 6 months * Unwilling to sign a consent

Design outcomes

Primary

MeasureTime frame
The number of Lung cancers5 years
Number of nodules5 years
Change in quality of life5 Years

Secondary

MeasureTime frame
Cancer detection rate5 years
Types and number of investigations5 Years

Countries

Australia, Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026